Dr. Bilinsky joined us as Chief Business Officer in September 2019. He has over 20 years of experience as a senior executive and consultant to the biotechnology industry. Most recently, Dr. Bilinskyserved as Chief Operating Officer of AmpliPhi Biosciences, a biotechnology company developing targeted therapies for patients with life-threatening bacterial infections. Previously, he was General Manager, Immuno-Oncology, and Senior Vice President, Special Operations and Research Operations, at Ignyta, a biotechnology company focused on precision medicine in oncology that was acquired by Roche. Prior to joining Ignyta, Dr. Bilinsky was Senior Vice President, Corporate Development at Vical, Vice President, Business Development and Special Operations at Halozyme Therapeutics, and Chief Executive Officer of Androclus Therapeutics. Dr. Bilinsky was previously a principal in the healthcare practice of Boston Consulting Group, where he advised companies in the biotechnology and pharmaceutical industries on business strategy, operational performance and mergers and acquisitions. Dr. Bilinsky received his B.S. in physics from the Moscow Institute of Physics and Technology and his Ph.D. in physics from the Massachusetts Institute of Technology.